Targeting breast cancer initiating cells: Advances in breast cancer research and therapy

Advances in Biological Regulation

Volumn 56, Issue , 2014, Pages 81-107

  McCubrey, James A ^a   Davis, Nicole M ^a   Abrams, Stephen L ^a   Montalto, Giuseppe ^b,c   Cervello, Melchiorre ^c   Libra, Massimo ^d   Nicoletti, Ferdinando ^d   D'Assoro, Antonino B ^e   Cocco, Lucio ^f   Martelli, Alberto M ^f   Steelman, Linda S ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e MAYO CLINIC CANCER CENTER   (United States)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cancer stem cells; ER; HER2; Hormonal therapy; MiRs; Targeted therapy; Therapy resistance

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN;

BREAST NEOPLASMS; CANCER STEM CELL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; PROTEINS;

EID: 84906766048     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2014.05.003     Document Type: Article

References (195)

1. Aceto N., Bentires-Alj M. Targeting protein-tyrosine phosphatases in breast cancer. Oncotarget 2012, 3:514-515.
2. Adams B.D., Guttilla I.K., White B.A. Involvement of microRNAs in breast cancer. Sem Reprod Med 2008, 26:522-536.
3. Akalay I., Janji B., Hasmim M., Noman M.Z., Andre F., De Cremoux P., et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013, 73:2418-2427.
4. Al-Ejeh F., Shi W., Miranda M., Simpson P.T., Vargas A.C., Song S., et al. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. JNucl Med 2013, 54:913-921.
5. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
6. Ali H.R., Dawson S.J., Blows F.M., Provenzano E., Pharoah P.D., Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011, 13:R118.
7. Anand A., Anand A. Paclitaxel in doxorubicin-resistant metastatic breast cancer patients. JNat Cancer Inst 1995, 87:1642.
8. Ao A., Morrison B.J., Wang H., Lopez J.A., Reynolds B.A., Lu J. Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments. PLoS One 2011, 6:e18810.
9. Arima Y., Hayashi N., Hayashi H., Sasaki M., Kai K., Sugihara E., et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 2012, 130:2568-2579.
10. Bai H., Xu R., Cao Z., Wei D., Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 2011, 585:402-408.
11. Baldwin R.M., Morettin A., Paris G., Goulet I., Cote J. Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells. Cell Cycle 2012, 11:4597-4612.
12. Baloh R.H., Tansey M.G., Lampe P.A., Fahrner T.J., Enomoto H., Simburger K.S., et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998, 21:1291-1302.
13. Banerjee A., Qian P., Wu Z.S., Ren X., Steiner M., Bougen N.M., et al. Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells. JBiol Chem 2012, 287:42502-42515.
14. Bhola N.E., Balko J.M., Dugger T.C., Kuba M.G., Sanchez V., Sanders M., et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. JClin Invest 2013, 123:1348-1358.
15. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
16. Bonofiglio D., Cione E., Vizza D., Perri M., Pingitore A., Qi H., et al. Bid as a potential target of apoptotic effects exerted by low doses of PPAR and RXR ligands in breast cancer cells. Cell Cycle 2011, 10:2344-2354.
17. Borgna S., Armellin M., di Gennaro A., Maestro R., Santarosa M. Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres. Cell Cycle 2012, 11:4242-4251.
18. Bressanin D., Evangelisti C., Ricci F., Tabellini G., Chiarini F., Tazzari P.L., et al. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget 2012, 3:811-823.
19. Bria E., Carlini P., Cuppone F., Vaccaro V., Milella M., Cognetti F. Early recurrence risk: aromatase inhibitors versus tamoxifen. Expert Rev Anticancer Ther 2010, 10:1239-1253.
20. Britton K.M., Eyre R., Harvey I.J., Stemke-Hale K., Browell D., Lennard T.W., et al. Breast cancer, side population cells and ABCG2 expression. Cancer Lett 2012, 323:97-105.
21. Buontempo F., Chiarini F., Bressanin D., Tabellini G., Melchionda F., Pession A., et al. Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle 2012, 11:2467-2475.
22. Cai W.Y., Wei T.Z., Luo Q.C., Wu Q.W., Liu Q.F., Yang M., et al. The Wnt-beta-catenin pathway represses let-7 microRNA expression through transactivation of Lin28 to augment breast cancer stem cell expansion. JCell Sci 2013, 126:2877-2889.
23. Caldon C.E., Sutherland R.L., Musgrove E. Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 2010, 9:1918-1928.
24. Chang S., Sharan S.K. Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1. Oncotarget 2012, 3:5-6.
25. Chappell W.H., Abrams S.L., Franklin R.A., Lahair M.M., Montalto G., Cervello M., et al. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle 2012, 11:4447-4461.
26. Chappell W.H., Abrams S.L., Montalto G., Cervello M., Martelli A.M., Candido S., et al. Effects of ectopic expression of NGAL on doxorubicin sensitivity. Oncotarget 2012, 3:1236-1245.
27. Chappell W.H., Lehmann B.D., Terrian D.M., Abrams S.L., Steelman L.S., McCubrey J.A. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle 2012, 11:4579-4588.
28. Chappell W.H., Abrams S.L., Stadelman K.M., Lahair M.M., Franklin R.A., Cocco L., et al. Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Adv Biol Regul 2013, 53:146-155.
29. Chaterjee M., van Golen K.L. Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy. Bone Marrow Res 2011, 362938.
30. Chen J.J., Shen H.C., Rivera Rosado L.A., Zhang Y., Di X., Zhang B. Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget 2012, 3:833-842.
31. Chen D., Bhat-Nakshatri P., Goswami C., Badve S., Nakshatri H. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res 2013, 73:5821-5833.
32. Chiarini F., Lonetti A., Teti G., Orsini E., Bressanin D., Cappellini A., et al. Acombination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget 2012, 3:1615-1628.
33. Cittelly D.M., Finlay-Schultz J., Howe E.N., Spoelstra N.S., Axlund S.D., et al. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene 2013, 32:2555-2564.
34. Cufi S., Vazquez-Martin A., Oliveras-Ferraros C., Martin-Castillo B., Joven J., Menendez J.A. Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010, 9:4461-4468.
35. Cufi S., Vazquez-Martin A., Oliveras-Ferraros C., Martin-Castillo B., Vellon L., Menendez J.A. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 2011, 10:3871-3885.
36. Cufi S., Vazquez-Martin A., Oliveras-Ferraros C., Corominas-Faja B., Urruticoechea A., Martin-Castillo B., et al. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget 2012, 3:1600-1614.
37. Cufi S., Corominas-Faja B., Vazquez-Martin A., Oliveras-Ferraros C., Dorca J., Bosch-Barrera J., et al. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012, 3:395-398.
38. Curtin N. PARP inhibitors for anticancer therapy. Biochem Soc Trans 2014, 42:82-88.
39. Cvek B., Dvorak Z. Targeting of nuclear factor-κB and proteasome by dithiocarbamate complexes with metals. Curr Pharm Des 2007, 13:3155-3167.
40. De Brot M., Rocha R.M., Soares F.A., Gobbi H. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. Pathology 2012, 44:303-312.
41. Dean J.L., McClendon A.K., Hickey T.E., Butler L.M., Tilley W.D., Witkiewicz A.K., et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by exvivo analyses of human tumors. Cell Cycle 2012, 11:2756-2761.
42. Deng X.S., Wang S., Deng A., Liu B., Edgerton S.M., Lind S.E., et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012, 11:367-376.
43. Droog M., Beelen K., Linn S., Zwart W. Tamoxifen resistance: from bench to bedside. Eur J Pharm 2013, 717:47-57.
44. Dulińska-Litewka J., McCubrey J.A., Laidler P. Increased AKT signaling resulting from the loss of androgen responsiveness in prostate cancer. Curr Med Chem 2013, 20:144-157.
45. D'Assoro A.B., Liu T., Quatraro C., Amato A., Opyrchal M., Leontovich A., et al. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha+ breast cancer cells. Oncogene 2014, 33:599-610.
46. Eckert M.A., Yang J. Targeting invadopodia to block breast cancer metastasis. Oncotarget 2011, 2:562-568.
47. Espina V., Mariani B.D., Gallagher R.I., Tran K., Banks S., Wiedemann J., et al. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS ONE 2010, 5:e10240.
48. Espina V., Wysolmerski J., Edmiston K., Liotta L.A. Attacking breast cancer at the preinvasion stage by targeting autophagy. Women's Health 2013, 9:157-170.
49. Faber A.C., Wong K.K., Engelman J.A. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010, 9:851-852.
50. Ferrari N., McDonald L., Morris J.S., Cameron E.R., Blyth K. RUNX2 in mammary gland development and breast cancer. JCell Physiol 2013, 228:1137-1142.
51. Follo M.Y., Marmiroli S., Faenza I., Fiume R., Ramazzotti G., Martelli A.M., et al. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS. Adv Biol Regul 2013, 52:2-6.
52. Follo M.Y., Faenza I., Piazzi M., Blalock W.L., Manzoli L., McCubrey J.A., et al. Nuclear PI-PLCβ1: an appraisal on targets and pathology. Adv Biol Regul 2014, 54:2-11.
53. Franklin R., Rodriquez-Mora O., La Hair M., McCubrey J.A. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxidants Redox Signal 2006, 8:1807-1817.
54. Fuller R., Branchey L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., et al. Disulfiram treatment of alcoholism: a veterans administration cooperative study". JAMA 1986, 256:1449-1455.
55. Gadalla S.E., Alexandraki A., Lindstrom M.S., Nister M., Ericsson C. Uncoupling of the ERalpha regulated morphological phenotype from the cancer stem cell phenotype in human breast cancer cell lines. Biochem Biophys Res Commun 2011, 405:581-587.
56. Gilani R.A., Kazi A.A., Shah P., Schech A.J., Chumsri S., Sabnis G., et al. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 2012, 135:681-692.
57. Gong C., Song E., Codogno P., Mehrpour M. The roles of BECN1 and autophagy in cancer are context dependent. Autophagy 2012, 8:1853-1855.
58. Gong C., Bauvy C., Tonelli G., Yue W., Delomenie C., Nicolas V., et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 2013, 32:2261-2272.
59. Guirouilh-Barbat J.K., Wilhelm T., Lopez B.S. AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. Oncotarget 2010, 1:691-699.
60. Guo M., Wang M., Zhang X., Deng H., Wang Z.Y. Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells. Anticancer Res 2013, 33:1873-1879.
61. Guo W.Z., Shiina I., Wang Y., Umeda E., Watanabe C., Uetake S., et al. Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway. Biochem Pharm 2013, 86:1272-1284.
62. Guttilla I.K., Adams B.D., White B.A. ERalpha, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endo Metab 2012, 23:73-82.
63. Guttilla I.K., Phoenix K.N., Hong X., Tirnauer J.S., Claffey K.P., White B.A. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 2012, 132:75-85.
64. Han M., Liu M., Wang Y., Chen X., Xu J., Sun Y., et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012, 7:e39520.
65. Harrison H., Rogerson L., Gregson H.J., Brennan K.R., Clarke R.B., Landberg G. Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-alpha status. Cancer Res 2013, 73:1420-1433.
66. Hashimoto K., Shimizu C., Tsuda H., Saji S., Osaki A., Shigekawa T., et al. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome. Oncology 2012, 82:168-174.
67. Hsu P.Y., Hsu H.K., Lan X., Juan L., Yan P.S., Labanowska J., et al. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell 2013, 24:197-212.
68. Huang S., Cai M., Zheng Y., Zhou L., Wang Q., Chen L. miR-888 in MCF-7 side population sphere cells directly targets E-cadherin. JGenet Genomics 2014, 41:35-42.
69. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Nat Acad Sci U S A 2011, 108:1397-1402.
70. Ithimakin S., Day K.C., Malik F., Zen Q., Dawsey S.J., Bersano-Begey T.F., et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab. Cancer Res 2013, 73:1635-1646.
71. Jiang Z., Jones R., Liu J.C., Deng T., Robinson T., Chung P.E., et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011, 10:1563-1570.
72. Jordan N.V., Johnson G.L., Abell A.N. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle 2011, 10:2865-2873.
73. Jung J.W., Park S.B., Lee S.J., Seo M.S., Trosko J.E., Kang K.S. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One 2011, 6:e28068.
74. Katz E., Sims A.H., Sproul D., Caldwell H., Dixon M.J., Meehan R.R., et al. Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget 2012, 3:608-619.
75. Kim S.H., Sehrawat A., Singh S.V. Dietary chemopreventative benzyl isothiocyanate inhibits breast cancer stem cells invitro and invivo. Cancer Prev Res 2013, 6:782-790.
76. Korkaya H., Wicha M.S. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res 2013, 73:3489-3493.
77. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
78. Kumar D., Shankar S., Srivastava R.K. Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms. Mol Cancer 2013, 12:171.
79. Kutanzi K.R., Koturbash I., Kovalchuk O. Reversibility of pre-malignant estrogen-induced epigenetic changes. Cell Cycle 2010, 9:3078-3084.
80. LaHair M.M., Howe C.J., Rodriguez-Mora O., McCubrey J.A., Franklin R.A. Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. Antioxid Redox Signal 2006, 8:1749-1756.
81. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. Acell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
82. Lawson D.A., Witte O.N. Stem cells in prostate cancer initiation and progression. JClin Invest 2007, 117:2044-2050.
83. Lee E.K., Diehl J.A. Breast cancer go sMAD: cyclin towards aggressive phenotypes. Cell Cycle 2011, 10:187.
84. Lee J.T., Lehmann B.D., Terrrian D.M., Chappell W.H., Stivala F., Libra M., et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008, 7:1745-1762.
85. Lee L.M., Cao J., Deng H., Chen P., Gatalica Z., Wang Z.Y. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 2008, 28:479-483.
86. Lehmann B.D., McCubrey J.A., Jefferson H.S., Paine M.S., Chappell W.H., Terrian D.M. Adominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007, 6:595-605.
87. Lehn S., Ferno M., Jirstrom K., Ryden L., Landberg G. Anon-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle 2011, 10:956-962.
88. Leontovich A.A., Zhang S., Quatraro C., Iankov I., Veroux P.F., Gambino M.W., et al. Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. Int J Oncol 2012, 40:1858-1864.
89. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913.
90. Lin Y., Zhong Y., Guan H., Zhang X., Sun Q. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. JExp Clin Cancer Res 2012, 31:59.
91. Liu F. Inhibition of Smad3 activity by cyclin D-CDK4 and cyclin E-CDK2 in breast cancer cells. Cell Cycle 2011, 10:186.
92. Liu B., Fan Z., Edgerton S.M., Yang X., Lind S.E., Thor A.D. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle 2011, 10:2959-2966.
93. Liu C., Luo Y., Liu X., Lu P., Zhao Z. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer. Cancer Biother Radiopharm 2012, 27:324-328.
94. Liu P., Kumar I.S., Brown S., Kannappan V., Tawari P.E., Tang J.Z., et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer 2013, 109:1876-1885.
95. Ma S., Guan X.Y. MiRegulators in cancer stem cells of solid tumors. Cell Cycle 2011, 10:571-572.
96. Mai T.T., Moon J., Song Y., Viet P.Q., Phuc P.V., Lee J.M., et al. Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells. Cancer Lett 2012, 321:144-153.
97. Mailtand N.J., Collins A.T. Prostate cancer stem cells: a new target of therapy. JClin Oncol 2007, 26:2862-2870.
98. Malik F., Korkaya H., Clouthier S.G., Wicha M.S. Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle 2012, 11:2780-2781.
99. Marian C.O., Shay J.W. Prostate tumor-initiating cells: a new target for telomerase inhibition therapy?. Biochim Biophys Acta 2009, 1792:289-296.
100. Marotta L.L., Polyak K. Unraveling the complexity of basal-like breast cancer. Oncotarget 2011, 2:588-589.
101. Martelli A.M., Chiarini F., Evangelisti C., Ognibene A., Bressanin D., Billi A.M., et al. Targeting the liver kinase B1/AMP-dependent kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opin Ther Target 2012, 16:729-742.
102. Martelli A.M., Chiarini F., Evangelisti C., Cappellini A., Buontempo F., Bressanin D., et al. Dual inhibitors of phosphatidylinositol 3-kinase and mammalian target of rapamycin: a novel therapeutic strategy for acute leukemia treatment?. Oncotarget 2012, 3:371-394.
103. Martelli A.M., Lonetti A., Amadori S., McCubrey J.A., Chiarini F. Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients. Cell Cycle 2013, 12:1815-1816.
104. Martin-Castillo B., Oliveras-Ferraros C., Vazquez-Martin A., Cufí S., Moreno J.M., Corominas-Faja B., et al. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (herceptin). Cell Cycle 2013, 12:225-245.
105. Martinez-Outschoorn U.E., Trimmer C., Lin Z., Whitaker-Menezes D., Chiavarina B., Zhou J., et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 2010, 9:3515-3533.
106. Martinez-Outschoorn U.E., Lin Z., Whitaker-Menezes D., Howell A., Lisanti M.P., Sotgia F. Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle 2012, 11:3956-3963.
107. Martinez-Outschoorn U.E., Lin Z., Whitaker-Menezes D., Howell A., Sotgia F., Lisanti M.P. Ketone body utilization drives tumor growth and metastasis. Cell Cycle 2012, 11:3964-3971.
108. Marty M., Fumoleau P., Adenis A., Rousseau Y., Merrouche Y., Robinet G., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001, 12:1643-1649.
109. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284.
110. McCubrey J.A., Sokolosky M.L., Lehmann B.D., Taylor J.R., Navolanic P.M., Chappell W.H., et al. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an Achilles heel by sensitization to targeted therapy. Adv Enzym Regul 2008, 48:113-135.
111. McCubrey J.A., Abrams S.L., Umezawa K., Cocco L., Martelli A.M., Franklin R.A., et al. Novel approaches to target cancer initiating cells-Eliminating the root of the cancer. Adv Bioc Regul 2012, 52:249-264.
112. McCubrey J.A., Steelman L.S., Abrams S.L., Misaghian N., Chappell W.H., Basecke J., et al. Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr Pharm Des 2012, 18:1784-1795.
113. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Franklin R.A., Montalto G., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012, 3:1068-1111.
114. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Montalto G., Cervello M., et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012, 3:954-987.
115. McCubrey J.A., Steelman L.S., Chappell W.H., Sun L., Davis N.M., Abrams S.L., et al. Advances in targeting signal transduction pathways. Oncotarget 2012, 3:1505-1521.
116. McCubrey J.A., Davis N.M., Abrams S.L., Montalto G., Cervello M., Basecke J., et al. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul 2014, 54:176-196.
117. McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Abrams S.L., Montalto G., et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 2014, 28:15-33.
118. McGee A.M., Douglas D.L., Liang Y., Hyder S.M., Baines C.P. The mitochondrial protein C1qbp promotes cell proliferation, migration and resistance to cell death. Cell Cycle 2011, 10:4119-4127.
119. Melchor L., Benitez J. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis 2008, 29:1475-1482.
120. Melchor L., Molyneux G., Mackay A., Magnay F.A., Atienza M., Kendrick H., et al. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol 2014, 233:124-137.
121. Menendez J.A., Oliveras-Ferraros C., Cufi S., Corominas-Faja B., Joven J., Martin-Castillo B., et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 2012, 11:2782-2792.
122. Minn A.J., Bevilacqua E., Yun J., Rosner M.R. Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle 2012, 11:2452-2457.
123. Mitra S., Stemke-Hale K., Mills G.B., Claerhout S. Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. Cancer Sci 2012, 103:400-407.
124. Molyneux G., Geyer F.C., Magnay F.A., McCarthy A., Kendrick H., Natrajan R., et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417.
125. Montales M.T., Rahal O.M., Kang J., Rogers T.J., Prior R.L., Wu X., et al. Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis 2012, 33:652-660.
126. Munz M., Baeuerle P.A., Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69:5627-5629.
127. Musgrove E.A., Sutherland R.L. RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease. Cell Cycle 2010, 9:4607-4615.
128. Nakanishi T., Ross D.D. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer 2012, 31(2):73-99.
129. Navolanic P.M., McCubrey J.A. Pharmacological breast cancer therapy. Int J Oncol 2005, 27:1341-1344.
130. Neri L.M., Cani A., Martelli A.M., Simioni C., Junghanss C., Tabellini G., et al. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia 2014, 28:739-748.
131. Oliveras-Ferraros C., Cufi S., Vazquez-Martin A., Torres-Garcia V.Z., Del Barco S., Martin-Castillo B., et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGF-induced oncomiR miRNA-181a. Cell Cycle 2011, 10:1144-1151.
132. Oliveras-Ferraros C., Corominas-Faja B., Cufi S., Vazquez-Martin A., Martin-Castillo B., Iglesias J.M., et al. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (herceptin). Cell Cycle 2012, 11:4020-4032.
133. Oliveras-Ferraros C., Cufi S., Vazquez-Martin A., Menendez O.J., Bosch-Barrera J., Martin-Castillo B., et al. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle 2012, 11:865-870.
134. Oplustilova L., Wolanin K., Mistrik M., Korinkova G., Simkova D., Bouchal J., et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012, 11:3837-3850.
135. Osborne C.K., Wiebe V.J., McGuire W.L., Ciocca D.R., DeGregorio M.W. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. JClin Oncol 1992, 10:304-310.
136. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. NEngl J Med 2008, 358:1409-1411.
137. Pajic M., Kersbergen A., van Diepen F., Pfauth A., Jonkers J., Borst P., et al. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells invivo. Cell Cycle 2010, 9:3780-3791.
138. Palmer N.P., Schmid P.R., Berger B., Kohane I.S. Agene expression profile of stem cell pluripotentiality and differentiation is conserved across diverse solid and hematopoietic cancers. Genome Biol 2012, 21, 13:R71.
139. Papi A., Guarnieri T., Storci G., Santini D., Ceccarelli C., Taffurelli M., et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ 2012, 19:1208-1219.
140. Perez R., Schally A.V., Vidaurre I., Rincon R., Block N.L., Rick F.G. Antagonists of growth hormone-releasing hormone suppress invivo tumor growth and gene expression in triple negative breast cancers. Oncotarget 2012, 3:988-997.
141. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cells. Nat Rev Cancer 2009, 9:265-273.
142. Pritchard K.I. Endocrine therapy: is the first generation of targeted drugs the last?. JIntern Med 2013, 274:144-152.
143. Qian P., Banerjee A., Wu Z.S., Zhang X., Wang H., Pandey V., et al. Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. Cancer Res 2012, 72:6036-6050.
144. Radojicic J., Zaravinos A., Vrekoussis T., Kafousi M., Spandidos D.A., Stathopoulos E.N. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011, 10:507-517.
145. Raven J.F., Williams V., Wang S., Tremblay M.L., Muller W.J., Durbin J.E., et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 2011, 10:794-804.
146. Rodriguez-Mora O., LaHair M.M., Howe C.J., McCubrey J.A., Franklin R.A. The calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. Exp Opin Thera Targ 2005, 9:791-808.
147. Rottenberg S., Jaspers J.E., Kersbergen A., van der Burg E., Nygren A.O., Zander S.A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U. S. A 2008, 105:17079-17084.
148. Rudloff U., Samuels Y. Agrowing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 2010, 9:1487-1503.
149. Sainsbury R. The development of endocrine therapy for women with breast cancer. Cancer Treat Rev 2013, 39:507-517.
150. Salem A.F., Whitaker-Menezes D., Howell A., Sotgia F., Lisanti M.P. Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle 2012, 11:4174-4180.
151. Salem A.F., Whitaker-Menezes D., Lin Z., Martinez-Outschoorn U.E., Tanowitz H.B., Al-Zoubi M.S., et al. Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. Cell Cycle 2012, 11:2545-2556.
152. Sanchez-Alvarez R., Martinez-Outschoorn U.E., Lamb R., Hulit J., Howell A., Gandara R., et al. Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. Cell Cycle 2013, 12:172-182.
153. Sendur M.A., Zengin N., Aksoy S., Altundag K. Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin 2014, 30:75-87.
154. Shafee N., Smith C.R., Wei S., Kim Y., Mills G.B., Hortobagyi G.N., et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008, 68:3243-3250.
155. Shimo T., Kurebayashi J., Kanomata N., Yamashita T., Kozuka Y., Moriya T., et al. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells. Breast Cancer 2014, 21:75-85.
156. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
157. Simioni C., Neri L.M., Tabellini G., Ricci F., Bressanin D., Chiarini F., et al. Activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012, 26:2336-2342.
158. Simoes B.M., Vivanco M.D. Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen. Future Oncol 2011, 7:995-1006.
159. Singer C.F., Zabkova P., Rappaport C., Muhr D., Pfeiler G., Gschwantler-Kaulich D., et al. Presence of intratumoral stem cells in breast cancer patients with or without BRCA germline mutations. Curr Cancer Drug Target 2012, 12:44-50.
160. Smalley M.J., Reis-Filho J.S., Ashworth A. BRCA1 and stem cells: tumour typecasting. Nat Cell Biol 2008, 10:377-379.
161. Sokolosky M., Chappell W.H., Stadelman K., Abrams S.L., Davis N.M., Steelman L.S., et al. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. Cell Cycle 2014, 13:820-833.
162. Sotgia F., Whitaker-Menezes D., Martinez-Outschoorn U.E., Flomenberg N., Birbe R.C., Witkiewicz A.K., et al. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. Cell Cycle 2012, 11:1445-1454.
163. Steelman L.S., Navolanic P.N., Sokolosky M., Taylor J.R., Lehmann B.D., Chappell W.H., et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity of mTOR inhibitors. Oncogene 2008, 27:4086-4095.
164. Steelman L.S., Navolanic P., Chappell W.H., Abrams S.L., Wong E.W., Martelli A.M., et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011, 10:3003-3015.
165. Sun X., Qin S., Fan C., Xu C., Du N., Ren H. Let-7: a regulator of the ERalpha signaling pathway in human breast tumors and breast cancer stem cells. Onc Rep 2013, 29:2079-2087.
166. Tan E.Y., Thike A.A. Breast Surgical Team at Outram, Tan PH. ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome. Br J Cancer 2013, 109:109-113.
167. Tanner M., Kapanen A.I., Junttila T., Raheem O., Grenman S., Elo J., et al. Characterization of a novel cell line established from a patient with herceptin-resistant breast cancer. Mol Cancer Ther 2004, 3:1585-1592.
168. Tarasewicz E., Jeruss J.S. Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle 2012, 11(13):2443-2451.
169. Tian B., Zhang Y., Li N., Liu X., Dong J. CD74: a potential novel target for triple-negative breast cancer. Tumour Biol 2012, 33:2273-2277.
170. Tsukabe M., Shimazu K., Morimoto K., Naoi Y., Kagara N., Shimoda M., et al. Clinicopathological analysis of breast ductal carcinoma in situ with ALDH1-positive cancer stem cells. Oncology 2013, 85:248-256.
171. Valastyan S., Weinberg R.A. miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 2010, 9:2124-2129.
172. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Del Barco S., Martin-Castillo B., Menendez J.A. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010, 9:3807-3814.
173. Vazquez-Martin A., Oliveras-Ferraros C., Del Barco S., Martin-Castillo B., Menendez J.A. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011, 126:355-364.
174. Vazquez-Martin A., Lopez-Bonetc E., Cufi S., Oliveras-Ferraros C., Del Barco S., Martin-Castillo B., et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 2011, 14:212-223.
175. Vazquez-Martin A., Cufi S., Lopez-Bonet E., Corominas-Faja B., Cuyas E., Vellon L., et al. Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. Cell Cycle 2013, 12:3471-3477.
176. Wang X., Baloh R.H., Milbrandt J., Garcia K.C. Structure of artemin complexed with its receptor GFRalpha3: convergent recognition of glial cell line-derived neurotrophic factors. Structure 2006, 146:1083-1092.
177. Wang K.H., Kao A.P., Lin T.C., Chang C.C., Kuo T.C. Promotion of epithelial-mesenchymal transition and tumor growth by 17beta-estradiol in an ER(+)/HER2(+) cell line derived from human breast epithelial stem cells. Biotech Appl Biochem 2012, 59:262-267.
178. Wang J., Gildea J.J., Yue W. Aromatase overexpression induces malignant changes in estrogen receptor alpha negative MCF-10A cells. Oncogene 2013, 32:5233-5240.
179. Warin R., Chambers W.H., Potter D.M., Singh S.V. Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate. Cancer Res 2009, 69:9473-9480.
180. Whitaker-Menezes D., Martinez-Outschoorn U.E., Flomenberg N., Birbe R.C., Witkiewicz A.K., Howell A., et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011, 10:4047-4064.
181. Witkiewicz A.K., Knudsen E.S. RB pathway and therapeutic sensitivity: new insights in breast cancer and tamoxifen therapy. Cell Cycle 2011, 10:1525.
182. Witkiewicz A.K., Whitaker-Menezes D., Dasgupta A., Philp N.J., Lin Z., Gandara R., et al. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012, 11:1108-1117.
183. Wright C., Moore R.D. Disulfiram treatment of alcoholism. Am J Med 1990, 88:647-655.
184. Xu W.R., Lin H.S., Chen X.Y., Zhang Y. Estrogen receptor of breast cancer stem cells depending on the original breast cancers. Med Hypothes 2011, 77:71-73.
185. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68:425-433.
186. Yenigun V.B., Ozpolat B., Kose G.T. Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen- and doxorubicin-induced autophagy. Int J Mol Med 2013, 31:1477-1483.
187. Yin S., Xu L., Bandyopadhyay S., Sethi S., Reddy K.B. Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol 2011, 39:891-898.
188. Yin S., Xu L., Bonfil R.D., Banerjee S., Sarkar F.H., Sethi S., et al. Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol Cancer Ther 2013, 12:491-498.
189. Yoo Y.D., Han D.H., Jang J.M., Zakrzewska A., Kim S.Y., Choi C.Y., et al. Molecular characteristics of cancer stem-like cells derived from human breast cancer cells. Anticancer Res 2013, 33:763-777.
190. Yu K.R., Yang S.R., Jung J.W., Kim H., Ko K., Han D.W., et al. CD49f enhances multipotency and maintains stemness through the direct regulation of OCT4 and SOX2. Stem Cells 2012, 30:876-887.
191. Yu K.D., Zhu R., Zhan M., Rodriguez A.A., Yang W., Wong S., et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res 2013, 19:2723-2733.
192. Yue W., Hamai A., Tonelli G., Bauvy C., Nicolas V., Tharinger H., et al. Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance. Autophagy 2013 May, 9(5):714-729.
193. Zhang F., Rothermund K., Gangadharan S.B., Pommier Y., Prochownik E.V., Lazo J.S. Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target. Oncotarget 2012, 3:998-1010.
194. Zhang Y., Eades G., Yao Y., Li Q., Zhou Q. Estrogen receptor alpha signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. JBiol Chem 2012, 287:41514-41522.
195. Zhong S., Li W., Chen Z., Xu J., Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 2013, 531:8-14.